Dysregulation of SIRT3 SUMOylation Confers AML Chemoresistance via Controlling HES1-Dependent Fatty Acid Oxidation
Yirong Zhang1, Yajie Shen1,2, Weiqing Wei1
1Department of Biochemistry and Molecular Cell Biology, Shanghai Jiao Tong University School of Medicine, Shanghai 200025, China.
Abstract:
Sirtuin 3 (SIRT3) deacetylase is a key regulator for chemoresistance in acute myeloid leukemia (AML) cells due to its capability of modulating mitochondrial metabolism and reactive oxygen species (ROS). SIRT3 is de-SUMOylated by SUMO-specific peptidase 1 (SENP1), which enhances its deacetylase activity. Therefore, dysregulation of SIRT3 SUMOylation may lead to fortified chemoresistance in AML. Indeed, SIRT3 de-SUMOylation was induced by chemotherapeutic agents, which in turn, exacerbated resistance against chemotherapies in AML by activating SIRT3 via preventing its proteasome degradation. Furthermore, RNA-seq revealed that expression of a collection of genes was altered by SIRT3 de-SUMOylation including inhibition of transcription factor Hes Family BHLH Transcription Factor 1 (HES1), a downstream substrate of Notch1 signaling pathway, leading to increased fatty acids oxidation (FAO). Moreover, the SENP1 inhibitor momordin-Ic or HES1 overexpression synergized with cytarabine to eradicate AML cells in vitro and in xenograft mouse models. In summary, the current study revealed a novel role of SIRT3 SUMOylation in the regulation of chemoresistance in AML via HES1-dependent FAO and provided a rationale for SIRT3 SUMOylation and FAO targeted interventions to improve chemotherapies in AML.
Insights
Sirtuin 3 (SIRT3) SUMOylation regulates chemoresistance in acute myeloid leukemia (AML). Inhibiting SENP1 or overexpressing HES1 enhances chemotherapy efficacy by targeting fatty acid oxidation (FAO) in AML cells.
Area of Science:
- Molecular Biology
- Cancer Biology
- Biochemistry
Background:
- Sirtuin 3 (SIRT3) deacetylase activity influences chemoresistance in acute myeloid leukemia (AML) by regulating mitochondrial metabolism and reactive oxygen species (ROS).
- SUMO-specific peptidase 1 (SENP1) enhances SIRT3 deacetylase activity through de-SUMOylation.
- Dysregulation of SIRT3 SUMOylation is implicated in AML chemoresistance.
Purpose of the Study:
- To investigate the role of SIRT3 SUMOylation in regulating chemoresistance in acute myeloid leukemia (AML).
- To explore the underlying mechanisms involving fatty acid oxidation (FAO) and the Notch1 signaling pathway.
- To evaluate potential therapeutic strategies targeting SIRT3 SUMOylation and FAO in AML.
Main Methods:
- RNA sequencing (RNA-seq) to analyze gene expression changes.
- In vitro and in vivo experiments using AML cell lines and xenograft mouse models.
- Assessment of SIRT3 de-SUMOylation, HES1 expression, and FAO levels.
- Evaluation of drug synergy with cytarabine.
Main Results:
- Chemotherapeutic agents induced SIRT3 de-SUMOylation, increasing AML chemoresistance by preventing proteasome degradation.
- SIRT3 de-SUMOylation altered gene expression, inhibiting Hes Family BHLH Transcription Factor 1 (HES1) and increasing fatty acid oxidation (FAO).
- SENP1 inhibition (momordin-Ic) or HES1 overexpression synergized with cytarabine to eradicate AML cells.
Conclusions:
- SIRT3 SUMOylation plays a novel role in regulating AML chemoresistance through HES1-dependent FAO.
- Targeting SIRT3 SUMOylation and FAO presents a promising therapeutic strategy to enhance AML chemotherapy.
Related Concept Videos
Abnormal Proliferation
mTOR Signaling and Cancer Progression
The mTOR pathway or the...
Covalently Linked Protein Regulators
These groups modify specific amino acids in a protein....


